N/A N=11 Treatment of Acne Keloidalis Nuchae (Razor Bumps Behind the Neck) Using UV Light Therapy
Acne Keloidalis Nuchae
Primary: Percentage Change in Total AKN Lesions From Baseline to Week 16. — 49 percentage of lesion count reduction
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=30 A Randomized Comparative Study Evaluating the Tolerability and Efficacy of Two Topical Therapies for the Treatment of Keloids and Hypertrophic Scars
Keloid · Hypertrophic Scar · Cicatrix, Hypertrophic
Primary: Change in Lesion Volume — 40; 42; 32 Percent Change
Phase 2 N=51 Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia
Cicatricial Alopecia
Primary: Number of Participants With Treatment-Emergent Adverse Events — 0; 3 Participants
Phase 2 N=3 Afamelanotide in Patients Suffering With Acne Vulgaris
Acne Vulgaris
Primary: The Change in Number of Facial Inflammatory Acne-related Lesions. — 46; 23.7 Lesions
Phase 4 N=10 A Study Evaluating the Efficacy and Safety of Clascoterone Cream 1% in Skin of Color Patients With Acne
Acne Vulgaris
Primary: The Primary Endpoint of This Study is the Percent of Patients Who Achieved Clear (0) or Almost Clear (1) on IGA Scale at Week 16 — 78 percentage of participants — p=<0.008
Phase 4 N=19 Treatment of Keloids With Fractional Erbium Laser-Assisted 5-Fluorouracil Versus Laser-Assisted Corticosteroid
Keloid Scar
Primary: Change in Patient and Observer Scar Assessment Scale (POSAS) Score From Baseline to Final Visit — -20; -20.6 score on a scale
Phase 2 N=30 A Pilot Study of Apligraf for the Treatment and Prevention of Recurrence of Excised Keloids
Keloid
Primary: The Primary Purpose of This Study Will be to Gain Preliminary Safety Experience With Apligraf in the Keloid Indication. The Number of Participants Experiencing AEs is…
N/A N=40 Assessing and Improving Patient Knowledge About Keloid Scars (Keloids)
Keloid Scar
Primary: To Assess the Impact of an Educational Lecture on Knowledge About Keloid Scars by Comparing Mean Scores Between Knowledge Assessment Questionnaires Administered Before…
N/A N=10 Tripeptide/Hexapeptide Topical and Hybrid Laser Treatment for Acne Scarring
Acne Scars - Mixed Atrophic and Hypertrophic
Primary: Mean Change From Baseline in Erythema — -1.687; 5.730 units on a scale
N/A N=10 Dermatosis Papulosa Nigra
Facial Dermatoses · Seborrheic Keratoses
Primary: Percent Clearance of All Lesions — 88; 96; 92.5; 0 percentage of lesion clearance
N/A N=13 Pilot Study of Laser Hair Depilation for Pilonidal Disease
Pilonidal Disease
Primary: Tolerability of Laser Treatment — 2 score on a scale
Phase 4 N=20 Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA)
Central Centrifugal Cicatricial Alopecia
Primary: Mean Change in Physician Global Assessment of Improvement (PGA-I) — 0.07 score on a scale
Phase 2 N=20 Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris
Acne Vulgaris
Primary: Proportion of Patients With Moderate to Severe Hypopigmentation and Hyperpigmentation Assessed After Treatment — 0; 0 participants
Phase 4 N=100 Radiesse® Injectable Dermal Filler for the Treatment of Nasolabial Folds in Persons of Color
Nasolabial Folds
Primary: Number Participants With Hypertropic Scarring, Keloid Formation, Hyper- or Hypopigmentation in Patients With Fitzpatrick Skin Types IV, V, and VI Receiving Nasolabial…
N/A N=60 Fractional Laser Assisted Steroid Therapy vs Intralesional Steroids in the Treatment of Keloids
Keloid
Primary: Mean Change in Composite Observer Score for Patient and Observer Scar Assessment Scale (POSAS) — -9.5; -8.9 score on a scale
N/A N=100 Knowledge Evaluation and Assessment of the Effectiveness of an Education Intervention on Acne
Acne Vulgaris
Primary: Number of Correct Responses to Questionnaire Items Immediately Before and After and Educational Lecture — 79; 79; 74; 79 participants
Early Phase 1 N=4 RAPA-Keloid Study of Keloid Regression
Keloid
Primary: Change in Keloid Surface Area — 0.455; -0.039 cm2
N/A N=20 Efficacy and Safety of Tixel Treatment on Facial and/or Scalp Actinic Keratoses.
Actinic Keratoses
Primary: Efficacy of Tixel for Treatment of Actinic Keratosis — -90.4 percentage change
N/A N=20 Evaluation of the Picosure 755nm Alexandrite Laser With Lens Array for the Treatment of Acne Scars
Acne Scars
Primary: Severity Change in Acne Scarring — -2 score on a scale
Phase 2 N=20 Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars
Acne Scars
Primary: Global Scarring Severity — 2.7 units on a scale
N/A N=4 Comparison of 1,550-nm Laser and Fractional Radiofrequency Microneedle for the Treatment of Acne Scars in Ethnic Skin
Acne Scars
Primary: Improvement in Acne Scarring - From Baseline to Three Months After Last Treatment — 2; 2 score on a scale
N/A N=14 Clinical Evaluation of Fractional Radiofrequency for the Treatment Acne Scarring
Acne Scars
Primary: Acne Scar Improvement — 0.26 units on a scale
Phase 2 N=274 Microneedle Lesion Preparation Prior to Aminolevulinic Acid Photodynamic Therapy (ALA-PDT) for AK on Face
Actinic Keratosis
Primary: Complete Clearance Rate — 16; 15; 10; 12 AK Fields
N/A N=25 Clinical Evaluation of Fractional Radiofrequency for the Treatment of Acne Scarring
Acne Scars
Primary: Overall Acne Scar Improvement Assessed by the Global Aesthetic Improvement Scale (GAIS) at 12 Weeks. — 1.06; 0.85 score on a scale
Phase 4 N=123 AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation
Acne Vulgaris
Primary: Absolute Change From Baseline in Post-Inflammatory Hyperpigmentation (PIH) Overall Disease Severity (ODS) Scores at Week 24 — -2.1; -2.1 score on a scale
N/A N=29 Pre-Shave Gel and Brush in Pseudofolliculitis Barbae
Pseudofolliculitis Barbae
Primary: Patient Global Severity Assessment- Mechanics of Shaving — 12.9; 12.4; 8.5; 9.7 score on a scale
N/A N=30,901 Healthcare Disparities in Alopecia Areata
Alopecia Areata
Primary: Likelihood of Depressive Episodes — 1217; 3576 Participants
N/A N=42 The Use of Bellafill for Atrophic Acne Scar Correction in the Full Facial Area
Atrophic Acne Scarring
Primary: Change on the Acne Scar Assessment Scale (ASAS) — 3.33; 2.19; 2.20 units on a scale
Phase 4 N=20 Efficacy and Safety Study of Finacea to Treat Acne Vulgaris and Post-Inflammatory Hyperpigmentation (PIH)
Acne Vulgaris · Post Inflammatory Hyperpigmentation
Primary: Percentage of Participants With Improvement in Acne IGA (Investigator Global Assessment) — 92 percentage of participants
Phase 3 N=490 Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs)
Actinic Keratosis
Primary: Number of Participants With Complete Clearance of AK Lesions — 55; 41; 9 participants